Vanguard reports 5.97% stake in Recursion Pharma

Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of 31,369,274 shares of Recursion Pharmaceuticals Inc. common stock on a passive ownership basis.

Rhea-AI Filing Summary

Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of 31,369,274 shares of Recursion Pharmaceuticals Inc. common stock on a passive ownership basis. This represents 5.97% of the class as of June 30, 2026.

Vanguard has sole voting power over 237,675 shares and sole dispositive power over 31,369,274 shares, with no shared voting or dispositive power. The position reflects securities held by Vanguard funds and managed accounts, and no other single person’s interest in these securities exceeds 5% of the class.

Key Figures

Beneficial ownership: 31,369,274 shares Percent of class: 5.97% Sole voting power: 237,675 shares +3 more

6 metrics

Beneficial ownership 31,369,274 shares Common stock beneficially owned by Vanguard Portfolio Management and affiliates

Percent of class 5.97% Portion of Recursion Pharmaceuticals common stock class held by Vanguard

Sole voting power 237,675 shares Shares for which Vanguard Portfolio Management has sole power to vote or direct the vote

Shared voting power 0 Shares for which Vanguard Portfolio Management has shared voting power

Sole dispositive power 31,369,274 shares Shares for which Vanguard Portfolio Management has sole power to dispose or direct disposition

Shared dispositive power 0 Shares for which Vanguard Portfolio Management has shared dispositive power

Key Terms

beneficially owned, dispositive power, sole voting power, percent of class, +1 more

5 terms

beneficially owned financial

"this reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

dispositive power financial

"exercises dispositive power, in addition to securities held by clients over which"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

sole voting power financial

"Sole Voting Power 237,675.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

percent of class financial

"Percent of class: 5.97 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

Schedule 13G regulatory

"Ownership of more than 5 Percent on Behalf of Another Person."

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Recursion Pharmaceuticals (RXRX) shares does Vanguard Portfolio Management report owning?

Vanguard Portfolio Management reports beneficial ownership of 5.97% of Recursion Pharmaceuticals common stock. This stake represents 31,369,274 shares held across Vanguard funds and managed accounts with dispositive power consolidated under Vanguard Portfolio Management.

How many RXRX shares does Vanguard Portfolio Management beneficially own?

Vanguard Portfolio Management reports beneficial ownership of 31,369,274 shares of Recursion Pharmaceuticals common stock. These holdings include securities in Vanguard funds and other managed accounts over which Vanguard or its specified affiliates exercise dispositive power.

What voting power does Vanguard Portfolio Management have over its RXRX holdings?

Vanguard Portfolio Management has sole voting power over 237,675 shares of Recursion Pharmaceuticals and no shared voting power. It has sole dispositive power over 31,369,274 shares, indicating authority to decide on sales or other dispositions for that full amount.

Is any other person reported to have more than 5% interest in Vanguard’s RXRX holdings?

No. The filing states that no one other person's interest in the securities reported is more than 5%. Rights to dividends or sale proceeds are spread across Vanguard investment companies and other managed accounts, none individually exceeding that threshold.

Which Vanguard entities are included in the RXRX Schedule 13G filing?

The filing covers securities beneficially owned, or deemed owned, by Vanguard Portfolio Management LLC and affiliates, including Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, where these entities exercise dispositive and/or voting power over the reported shares.

Where are the principal offices of Recursion Pharmaceuticals (RXRX) and Vanguard Portfolio Management?

Recursion Pharmaceuticals’ principal executive offices are at 41 South Rio Grande Street, Salt Lake City, UT 84101. Vanguard Portfolio Management’s principal business office is at 100 Vanguard Blvd., Malvern, PA 19355, as stated in the Schedule 13G filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 11:40 AM Accepted by SEC EDGAR 07/31/2026 - 11:40 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Recursion Pharmaceuticals Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

75629V104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 75629V104

1

Names of Reporting Persons

Vanguard Portfolio Management

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 237,675.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 31,369,274.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

31,369,274.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.97 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Portfolio Management LLC and the following affiliates of Vanguard Portfolio Management LLC or business divisions of such affiliates: Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Portfolio Management LLC, or business divisions of such subsidiaries whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Recursion Pharmaceuticals Inc
(b)	Address of issuer's principal executive offices: 41 South Rio Grande Street, Salt Lake City, UT, 84101
Item 2.
(a)	Name of person filing: Vanguard Portfolio Management
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 75629V104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 31369274
(b)	Percent of class: 5.97 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 237675
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 31369274
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Vanguard Portfolio Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vanguard Portfolio Management

Signature:	My Trieu-Gatt
Name/Title:	Authorized Signatory, Head of Global Fund Administration
Date:	07/31/2026